LGVN
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- P/S ratio of 28.33 is excessive
- P/B ratio of 4.70 is high for a non-earning entity
- No Graham Number available due to lack of earnings
Ref Growth rates
- Analyst target price suggests high potential upside if clinical milestones are met
- Revenue growth is declining sharply (-39.50%)
- Forward P/E is negative
Ref Historical trends
- 5-year price change of -98.3%
- Consistent history of earnings misses and deep losses
Ref Altman Z-Score, Piotroski F-Score
- Low debt levels
- Current ratio > 1.0
- Piotroski F-Score of 1/9 indicates severe fundamental weakness
- ROE of -164.75% shows massive capital erosion
Ref Yield, Payout
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LGVN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LGVN
Longeveron Inc.
Primary
|
-98.3% | -96.0% | -14.1% | +42.7% | +42.7% | +8.4% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
ATRA
Atara Biotherapeutics, Inc.
Peer
|
-98.9% | -95.6% | -24.7% | -54.9% | -70.3% | +15.0% |
|
BDMD
Baird Medical Investment Holdings Limited
Peer
|
-89.3% | -90.0% | -87.4% | -49.5% | -26.9% | -10.4% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LGVN
Longeveron Inc.
|
BEARISH | $33.97M | - | -164.7% | -% | $1.16 | |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
ATRA
Atara Biotherapeutics, Inc.
|
BEARISH | $37.64M | 1.83 | -% | 15.4% | $5.22 | Compare |
|
BDMD
Baird Medical Investment...
|
BEARISH | $37.83M | - | -8.0% | -10.0% | $1.03 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | WILLARD STEPHEN H | Chief Executive Officer | Stock Award | 400,000 | - |
Past News Coverage
Recent headlines mentioning LGVN from our newsroom.